Stock Analiz

Camp4 Therapeutics Corp CAMP

Biotechnology: Pharmaceutical Preparations · IPO 2024 · data as of November 13, 2026

$3.80Market cap $238M
Open the interactive analysis →

Camp4 Therapeutics Corp (CAMP) is a healthcare company listed in the US with a market value of about $238M. In the twelve months to September 30, 2026 it had revenue of $5M and net income of -$121M, a net margin of -2276.3%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -71%.

About Camp4 Therapeutics

Camp4 Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2024. It was profitable in 0 of the last 3 years in our data. It spends 1092% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S44.8
P/B2.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-11.1%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)436.5%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-8108.4%
ROIC (5-yr avg.)-71.1%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 3 years

Fiscal yearTTM202520242023
Revenue$5M$3M$652000$350000
Net income-$121M-$80M-$52M-$49M
Free cash flow-$26M-$30M-$46M-$45M
EPS (diluted)$-2.11$-1.32$-5.52$-62.40
Net margin-2276.3%-2298.5%-7943.4%-14083.1%
ROIC—-83.6%-58.6%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 9 analysts is $10.22, 169% above the current price; targets range from $6.00 to $15.00; the consensus rating is “Strong buy”; expected EPS is $-1.21 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Camp4 Therapeutics pay a dividend?

Not currently.

Is Camp4 Therapeutics a good stock to buy?

We do not give buy or sell advice. Camp4 Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.